​

Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TRDA Stock Forecast

Entrada Therapeutics (TRDA) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $16.00, with a high of $21.00 and a low of $10.00. This represents a 168.01% increase from the last price of $5.97.

$5 $9 $13 $17 $21 $25 High: $21 Avg: $16 Low: $10 Last Closed Price: $5.97

TRDA Stock Rating

Entrada Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (66.67%), 2 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 2 4 0 Strong Sell Sell Hold Buy Strong Buy

TRDA Price Target Upside V Benchmarks

TypeNameUpside
StockEntrada Therapeutics168.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts125
Avg Price Target$17.00$13.50$16.20
Last Closing Price$5.97$5.97$5.97
Upside/Downside184.76%126.13%171.36%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-71--8
May, 26-8---8
Apr, 26-7---7
Mar, 26-7---7
Feb, 26-6---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 08, 2026Guggenheim$17.00$6.37166.88%184.76%
May 08, 2026Roth Capital$10.00$6.6350.83%67.50%
Feb 10, 2026Guggenheim$20.00$10.8284.84%235.01%
Jan 28, 2026Kostas BiliourisOppenheimer$21.00$11.0090.91%251.76%
Nov 06, 2025Roth Capital$13.00$6.9587.05%117.76%
Feb 28, 2025Roth Capital$23.00$11.9492.63%285.26%
Nov 06, 2024Boobalan PachaiyappanH.C. Wainwright$20.00$18.0310.93%235.01%
Jun 25, 2024Raghuram SelvarajuH.C. Wainwright$18.00$14.2426.40%201.51%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 08, 2026H.C. WainwrightBuyNeutraldowngrade
Feb 10, 2026GuggenheimBuyinitialise
Jan 28, 2026OppenheimerOutperforminitialise
Aug 14, 2024Cowen & Co.BuyBuyhold
Jun 25, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024Cowen & Co.BuyBuyhold
Nov 22, 2023William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.20$1.76$-3.47---
Avg Forecast$-0.09$1.05$-3.09$-3.17$-4.50$-4.75
High Forecast$4.13$1.18$-2.66$-2.58$-3.11$-3.28
Low Forecast$-2.63$0.91$-3.58$-3.76$-6.07$-6.40
Surprise %122.22%67.62%12.30%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$129.01M$210.78M$25.42M---
Avg Forecast$110.88M$186.51M$46.74M$47.86M$174.22M$304.77M
High Forecast$119.28M$189.22M$58.45M$60.66M$220.83M$386.31M
Low Forecast$97.65M$184.74M$36.26M$36.47M$132.78M$232.28M
Surprise %16.35%13.01%-45.61%---

Net Income Forecast

$-250M $-170M $-90M $-10M $70M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.68M$65.63M$-143.75M---
Avg Forecast$-6.68M$34.63M$-103.05M$-104.79M$-151.60M$-156.99M
High Forecast$136.35M$39.14M$-87.88M$-85.16M$-102.74M$-108.44M
Low Forecast$-87.03M$30.13M$-118.22M$-124.43M$-200.45M$-211.59M
Surprise %-89.48%39.50%---

TRDA Forecast FAQ

Is Entrada Therapeutics stock a buy?

Entrada Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Entrada Therapeutics is a favorable investment for most analysts.

What is Entrada Therapeutics's price target?

Entrada Therapeutics's price target, set by 6 Wall Street analysts, averages $16 over the next 12 months. The price target range spans from $10 at the low end to $21 at the high end, suggesting a potential 168.01% change from the previous closing price of $5.97.

How does Entrada Therapeutics stock forecast compare to its benchmarks?

Entrada Therapeutics's stock forecast shows a 168.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Entrada Therapeutics over the past three months?

  • June 2026: 0% Strong Buy, 87.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Entrada Therapeutics’s EPS forecast?

Entrada Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.17, marking a -8.65% decrease from the reported $-3.47 in 2025. Estimates for the following years are $-4.5 in 2027, and $-4.75 in 2028.

What is Entrada Therapeutics’s revenue forecast?

Entrada Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $47.86M, reflecting a 88.25% increase from the reported $25.42M in 2025. The forecast for 2027 is $174.22M, and $304.77M for 2028.

What is Entrada Therapeutics’s net income forecast?

Entrada Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-105M, representing a -27.10% decrease from the reported $-144M in 2025. Projections indicate $-152M in 2027, and $-157M in 2028.